All NewsEducationTV
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Waters Corp. raises annual forecasts after beating Q2 estimates

Created at 4 Aug · 10:57 AM2 sources↑ Market-relevant2 events
IN SHORT

Waters Corp. raised its annual profit and revenue forecasts after exceeding second-quarter Wall Street estimates. The laboratory equipment maker reported higher demand for its products and better-than-expected growth from recently acquired businesses.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

$14.45 to $14.652026 adjusted profit per share forecast
$6.42 billion to $6.48 billion2026 revenue forecast
$3.05Q2 adjusted profit per share
$1.65 billionQ2 revenue
5%Q2 laboratory instrument sales growth
$817 millionQ2 revenue from acquired businesses
$3.95 to $4.05Q3 adjusted profit per share forecast
$1.75 billion to $1.76 billionQ3 revenue forecast

Who's Involved

Waters Corp.
Laboratory equipment maker that raised annual forecasts
Becton Dickinson
Seller of acquired biosciences and diagnostics businesses
Waters Corp. raises annual forecasts after beating Q2 estimates

↳ Why This Matters

Waters' upward revision of its financial outlook signals strong underlying demand in the laboratory equipment and diagnostics sectors, potentially indicating resilience in scientific research and healthcare spending.

Key facts

  • Waters raised its annual profit and revenue forecasts.
  • The company beat second-quarter Wall Street estimates for profit and revenue.
  • Demand for laboratory equipment and diagnostics contributed to the strong results.
  • Acquired businesses from Becton Dickinson performed well in their first full quarter under Waters' ownership.

Waters Corp. raised its annual profit and revenue forecasts after exceeding second-quarter Wall Street estimates, driven by increased demand for its laboratory equipment and better-than-expected performance from recently acquired businesses. The company now expects 2026 adjusted profit between $14.45 and $14.65 per share, and revenue between $6.42 billion and $6.48 billion. In the second quarter, Waters reported adjusted profit of $3.05 per share on revenue of $1.65 billion, surpassing analyst expectations. Sales of laboratory instruments rose 5%, while chemicals and testing supplies saw double-digit growth. The biosciences and diagnostics businesses, acquired from Becton Dickinson, generated $817 million in their first full quarter. Waters anticipates third-quarter adjusted profit between $3.95 and $4.05 per share and revenue of $1.75 billion to $1.76 billion.

Frequently asked questions

Waters now expects 2026 adjusted profit to be between $14.45 and $14.65 per share.

Higher demand for laboratory equipment and strong performance from recently acquired businesses contributed to the better-than-expected results.

Sales of laboratory instruments rose 5%, and chemicals and other testing supplies experienced double-digit growth.

Waters expects third-quarter revenue to be between $1.75 billion and $1.76 billion.

What Happens Next

01Waters will report third-quarter earnings.
02Analysts will update their financial models based on the new guidance.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence
CME Headlines
  • August 2026 Eligible Corporate Bonds, ETFs, USTETFs and Stocks - Effective August 03, 2026
    3 Aug · 8:57 PM
  • S&P 500 futures climbed near all-time highs on solid earnings.
    3 Aug · 8:52 PM
  • S&P 500 futures climbed near all-time highs on solid earnings.
    3 Aug · 8:52 PM

How It Developed

Pfizer exceeded quarterly profit expectations due to robust sales of its blood thinner, Eliquis.
Waters raised its annual profit and revenue forecasts for 2026.
Waters reported second-quarter adjusted profit of $3.05 per share, above analysts' estimate of $3.01.
Waters' quarterly revenue totaled $1.65 billion, exceeding the market estimate of $1.62 billion.
Sales of laboratory instruments rose 5% to $240 million, while chemicals and other testing supplies recorded double-digit growth.
Waters' acquired biosciences and diagnostics businesses generated $817 million in their first full quarter.
Waters expects third-quarter adjusted profit of $3.95 to $4.05 per share and revenue of $1.75 billion to $1.76 billion.

Sources

T1
Pfizer beats quarterly profit estimates on strong demand for blood thinner EliquisReuters
T2
Pfizeren.wikipedia.org

Related Stories

Archer-Daniels-Midland beats Q2 profit estimates on strong grain trading margins
4 Aug · 10:25 AM
Merck beats Q2 expectations on Keytruda sales, raises full-year forecast
4 Aug · 10:38 AM
Caterpillar profit jumps on strong power, construction equipment demand
4 Aug · 10:46 AM
DuPont raises annual profit forecast after beating quarterly estimates
4 Aug · 10:20 AM
Broadridge quarterly profit climbs on investor communications strength
4 Aug · 11:56 AM